Prevnar full dose schedule restored
Executive Summary
The Centers for Disease Control & Prevention reinstates full four-dose schedule for Wyeth's pneumococcal conjugate vaccine Prevnar Sept. 16. CDC recommended deferring the third and fourth doses because of supply problems; it reinstated the third dose recommendation in July (1"The Pink Sheet" July 12, 2004, In Brief). Wyeth CEO Robert Essner told the Bear Stearns health care conference Sept. 14 that Prevnar's supply issues were "under good control"...
You may also be interested in...
No News Is Good News For Wyeth: Smooth Quarter Will Beat Expectations
A lack of "negative surprises" for Wyeth during the first quarter is contributing to financial results well above analyst estimates, the company said
CDC recommends reinstating third Prevnar dose
Health care providers should reinstate administration of third dose of Wyeth's pneumococcal conjugate vaccinePrevnar for healthy children under two years old, Centers for Disease Control & Prevention says July 8. CDC recommended suspending the third and fourth doses of Prevnar in March due to a "markedly worse" than anticipated production shortfall in Wyeth's vial-filling process (1"The Pink Sheet" March 8, 2004, p. 25). CDC expects that Prevnar supply will be adequate for four-dose coverage in the fall (2"The Pink Sheet" June 7, 2004, p.30)...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.